Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03930602 · ClinicalTrials.gov registry record · Phase 1
Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03930602 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants.
The verdict
NCT03930602, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
To compare the pharmacokinetic characteristics of BMS-986165 after a single-dose administration alone vs. in combination with fluvoxamine (CYP1A2 inhibitor)
Interventions
- DRUG BMS-986165
- DRUG Fluvoxamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2019-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03930602
The ClinicalTrials.gov registry entry for NCT03930602 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986165 is the first listed.
NCT03930602 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03930602 about?
NCT03930602 is a clinical study titled "Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165". To compare the pharmacokinetic characteristics of BMS-986165 after a single-dose administration alone vs. in combination with fluvoxamine (CYP1A2 inhibitor)
What is the current status of trial NCT03930602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2019-05-01. Estimated completion is 2019-05-27.
What interventions are being tested in trial NCT03930602?
The interventions under investigation include: BMS-986165 (DRUG), Fluvoxamine (DRUG).
Who is sponsoring clinical trial NCT03930602?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.